Valthos, the NY-based startup founded by Kathleen McMahon and Tess van Stekelenburg, just broke stealth to take on one of the biggest existential questions of the AI era: what happens when intelligence, artificial or otherwise, starts playing with biology like it’s code? The round, co-led by OpenAI Startup Fund, Founders Fund, and Lux Capital, isn’t just another funding headline; it’s a firewall for the future.
Valthos was built for a world where biology moves at the speed of machine learning. McMahon, who ran Life Sciences at Palantir for 7 years, saw how data can rewire medicine from discovery to delivery. Van Stekelenburg, now a Partner at Lux Capital and an Oxford-trained computational neuroscientist, knew waiting for someone else to build this was a risk humanity couldn’t afford. Together, they founded Valthos in 2024 to do one thing with surgical precision: detect, design, and defend against AI-enabled biological threats before they happen.
Originally known as Project Biosecurity, the company evolved into Valthos, an applied biological intelligence powerhouse that turns raw data into early warning signals. Their AI models aggregate data from wastewater, air, and clinical sources, analyzing patterns to spot threats before they spread. And when they do? Valthos tech can generate updated vaccine or therapeutic blueprints in real time. It’s a full-stack biodefense system designed for speed, precision, and survival.
Jason Kwon of OpenAI called for “a system of countervailing technologies” to keep biosecurity resilient. Founders Fund’s Delian Asparouhov noted this kind of investment only makes sense now, AI’s ability to create and counter biological threats just hit parity. Lux Capital’s Brandon Reeves said it best: “We’re in the early innings.” If nuclear and cyber are Tier 1 threats, bio is next, and the inning clock is ticking fast.
The $30M raise will fuel team expansion across NY and SF, building infrastructure that connects AI, computational biology, and government-grade security. McMahon plans to bring Palantir-level operational discipline to partnerships with defense agencies and life sciences firms. The mission: meet operators where they are and give them tools that work under pressure. Valthos will also collaborate with pharma partners to move AI-designed countermeasures from code to clinic, because prevention is useless if it can’t be produced.
What makes this story hit different isn’t just the capital, it’s the convergence. AI, biotech, and national security just fused into one ecosystem, and Valthos is building the immune system for it.
